Kalinox (Nitrous Oxide, Oxygen)

Nitrous oxide produces its effects by blocking NMDA receptors and modulating opioid receptors in the central nervous system. This dual action reduces pain transmission and produces a calming effect. The accompanying oxygen ensures adequate tissue oxygenation, allowing safe use during brief procedures.

The specific concentration and duration of Kalinox administration are determined by the prescribing clinician based on the procedure, patient age, weight and clinical condition. Dosage is titrated to achieve the desired analgesic and sedative effect while maintaining safe oxygen saturation levels.

Safety data for nitrous oxide and oxygen use during pregnancy and lactation are limited. Because potential fetal effects are not well established, Kalinox should be used only when clearly needed and after careful risk‑benefit assessment by the treating physician.

To request Kalinox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

The primary alternative to Kalinox is intravenous opioid analgesia or other inhaled agents such as sevoflurane. Compared with IV opioids, nitrous oxide offers rapid onset and recovery, minimal respiratory depression when used with oxygen, and easier titration. Unlike other volatile anesthetics, Kalinox provides analgesia without deep unconsciousness, making it suitable for short procedures.

Kalinox cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep them in the original packaging, secure them upright, and protect the valve from damage. Follow local regulations for compressed gas storage and ensure cylinders are inspected regularly for leaks.

Kalinox is administered via a calibrated face mask or nasal hood that delivers a controlled mixture of nitrous oxide and oxygen. The clinician adjusts the flow rates to achieve the desired analgesic effect while continuously monitoring the patient’s vital signs and oxygen saturation throughout the procedure.

Serious risks include hypoxia if oxygen delivery is insufficient, respiratory depression, loss of consciousness, severe hypertension, seizures, and allergic reactions such as rash or anaphylaxis. Continuous monitoring of respiratory and cardiovascular status is essential to detect and manage these events promptly.

Kalinox is contraindicated in patients with known hypersensitivity to nitrous oxide or oxygen, severe chronic obstructive pulmonary disease, uncontrolled asthma, or those who cannot maintain adequate airway protection. Caution is also advised for individuals with vitamin B12 deficiency, recent ear surgery, or certain psychiatric conditions.